MLPA® Kits

For a description how to create and adapt MLPA Kits, that are not available on this page, please have a look at our User Manual MLPA.

Import of SALSA MLPA® kit descriptions via the SEQUENCE Pilot operation "Mixes [master file] / button [Import]".

Mix
Version
Date
Region
Application
Vs. 07
08-04-2010
Reference probes + control fragments Synthetic 'home-made' probes
Vs. 09
25-03-2012
Reference probes + control fragments Synthetic 'home-made' probes
Vs. 11
10-12-2012
Reference probes + control fragments Synthetic 'home-made' probes
Vs. 14
04-09-2015
Reference probes + control fragments Synthetic 'home-made' probes
Vs. 05
01-03-2013
Chr. 6, Chr. 14, Chr. 16, Chr. 17. Medulloblastoma
Vs. 06
27-09-2013
Chr. 6, Chr. 14, Chr. 16, Chr. 17. Medulloblastoma
Vs. 06
27-09-2013
Chr. 2, Chr. 3, Chr. 7, Chr. 9 Medulloblastoma
Vs. 06
27-09-2013
Chr. 1, Chr. 4, Chr. 5, Chr. 8, Chr. 10, Chr. 20 Medulloblastoma
Vs. 01
06-01-2009
IRF6 1q32.2 Van der Woude syndrome (VWS)
Vs. 02
04-12-2009
IRF6 1q32.2 Van der Woude syndrome (VWS)
Vs. 05
18-12-2012
IRF6 1q32.2 Van der Woude syndrome (VWS)
Vs. 07
10-02-2016
IRF6 1q32.2 Van der Woude syndrome (VWS)
Vs. 03
08-09-2009
AGXT, GRHPR Primary hyperoxaluria, type 1 (PH1) & type 2 (PH2)
P305-B1 Vs. 06 25-03-2012 AGXT, GRHPR Primary hyperoxaluria, type 1 (PH1) & type 2 (PH2)
P305-B2 Vs. 09 03-12-2013 AGXT, GRHPR Primary hyperoxaluria, type 1 (PH1) & type 2 (PH2)
P305-B2 Vs. 10 03-04-2014 AGXT, GRHPR Primary hyperoxaluria, type 1 (PH1) & type 2 (PH2)
P305-B2 Vs. 11 12-10-2016 AGXT, GRHPR Primary hyperoxaluria, type 1 (PH1) & type 2 (PH2)
Vs. 03
22-09-2010
SPG11 or KIAA1840 15q21.1 Hereditary spastic paraplegia (HSP or SPG)
Vs. 04
08-04-2011
SPG11 or KIAA1840 15q21.1 Hereditary spastic paraplegia (HSP or SPG)
Vs. 07
10-12-2012
SPG11 or KIAA1840 15q21.1 Hereditary spastic paraplegia (HSP or SPG)
Vs. 08
07-08-2015
SPG11 or KIAA1840 15q21.1 Hereditary spastic paraplegia (HSP or SPG)
Vs. 09
09-09-2015
SPG11 or KIAA1840 15q21.1 Hereditary spastic paraplegia (HSP or SPG)
Vs. 10
01-12-2017
SPG11 or KIAA1840 15q21.1 Hereditary spastic paraplegia (HSP or SPG)
Vs. 04
24-09-2011
SEPT9 17q25.3 Hereditary neuralgic amyotrophy (HNA)
Vs. 07
22-04-2015
SEPT9 17q25.3 Hereditary neuralgic amyotrophy (HNA)
Vs. 01
28-03-2013
MET 7q31, PTEN 10q23.31, LRRK2 12q12 Papillary renal carcinoma, various cancers
Vs. 02
07-08-2015
MET 7q31, PTEN 10q23.31, LRRK2 12q12 Papillary renal carcinoma, various cancers
Vs. 02
03-12-2009
MTM1 Xq28, MTMR1 Xq28 Myotubular myopathy, x-linked (XLMTM)
Vs. 05
02-12-2013
MTM1 Xq28, MTMR1 Xq28 Myotubular myopathy, x-linked (XLMTM)
Vs. 07
20-01-2017
MTM1 Xq28, MTMR1 Xq28 Myotubular myopathy, x-linked (XLMTM)
Vs. 07
18-06-2011
TCOF1 Treacher Collins-Franceschetti 1
Vs. 09
18-12-2012
TCOF1 Treacher Collins-Franceschetti 1
P310-B2 Vs. 11 20-11-2015 TCOF1 Treacher Collins-Franceschetti 1
P310-B3 Vs. 12 25-10-2017 TCOF1 Treacher Collins-Franceschetti 1
Vs. 02
26-11-2010
GATA4 8p23, NKX2-5 5q35, TBX5 12q24, BMP4 14q22, CRELD1 3p25 Congenital Heart Disease (CHD)
Vs. 05
10-12-2012
GATA4 8p23, NKX2-5 5q35, TBX5 12q24, BMP4 14q22, CRELD1 3p25 Congenital Heart Disease (CHD)
Vs. 06
07-08-2015
GATA4 8p23, NKX2-5 5q35, TBX5 12q24, BMP4 14q22, CRELD1 3p25 Congenital Heart Disease (CHD)
Vs. 07
29-07-2016
GATA4 8p23, NKX2-5 5q35, TBX5 12q24, BMP4 14q22, CRELD1 3p25 Congenital Heart Disease (CHD)
Vs. 04
25-03-2010
P450 oxireductase gene (POR) Congenital adrenal hyperplasia (CAH)
Vs. 05
07-03-2012
P450 oxireductase gene (POR) Congenital adrenal hyperplasia (CAH)
Vs. 07
13-08-2013
P450 oxireductase gene (POR) Congenital adrenal hyperplasia (CAH)
Vs. 05
03-12-2009
CREBBP 16p13.3 Rubinstein–Taybi syndrome (RSTS)
Vs. 09
26-03-2013
CREBBP 16p13.3 Rubinstein–Taybi syndrome (RSTS)
Vs. 10
07-08-2015
CREBBP 16p13.3 Rubinstein–Taybi syndrome (RSTS)
Vs. 11
21-10-2016
CREBBP 16p13.3 Rubinstein–Taybi syndrome (RSTS)
P315-B1
Vs. 06
19-12-2013
EGFR 7p11 Tumours, solid
Vs. 07
07-06-2011
SETX 9p34.13, APTX 9p13.3, FXN 9p13 Recessive Ataxias
P316-B2 Vs. 08 07-03-2012 SETX 9p34.13, APTX 9p13.3, FXN 9p13 Recessive Ataxias
P316-B2 Vs. 10 07-08-2015 SETX 9p34.13, APTX 9p13.3, FXN 9p13 Recessive Ataxias
P316-B2 Vs. 11 10-12-2015 SETX 9p34.13, APTX 9p13.3, FXN 9p13 Recessive Ataxias
P316-B2 Vs. 12 26-09-2016 SETX 9p34.13, APTX 9p13.3, FXN 9p13 Recessive Ataxias
Vs. 01
10-11-2009
PHOX2B, GFRA3, GFRA2, GFRA1, EDNRB, NRTN, PSPN, SOX10 Hirschsprung disease
Vs. 02
11-03-2012
PHOX2B, GFRA3, GFRA2, GFRA1, EDNRB, NRTN, PSPN, SOX10 Hirschsprung disease
Vs. 03
18-12-2012
PHOX2B, GFRA3, GFRA2, GFRA1, EDNRB, NRTN, PSPN, SOX10 Hirschsprung disease
Vs. 04
18-07-2014
PHOX2B, GFRA3, GFRA2, GFRA1, EDNRB, NRTN, PSPN, SOX10 Hirschsprung disease
Vs. 01
16-09-2009
TPO, PAX8, FOXE1, NKX2-1, TSHR Thyroid dysgenesis
P319-A1 Vs. 02 24-01-2011 TPO, PAX8, FOXE1, NKX2-1, TSHR Thyroid dysgenesis
P319-A2 Vs. 04 10-12-2012 TPO, PAX8, FOXE1, NKX2-1, TSHR Thyroid dysgenesis
P319-A2 Vs. 06 09-12-2015 TPO, PAX8, FOXE1, NKX2-1, TSHR Thyroid dysgenesis
P319-A2 Vs. 07 03-03-2017 TPO, PAX8, FOXE1, NKX2-1, TSHR Thyroid dysgenesis